-
1.发明授权Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis 有权通过诱变改变抗体的FcRn结合亲和力或血清半衰期公开(公告)号：US07217797B2
公开(公告)日：2007-05-15
申请号：US10687118
申请日：2003-10-15
CPC分类号： C07K16/082 , C07K16/00 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
摘要翻译： 本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于 其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。
-
2.发明授权Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis 有权通过诱变改变抗体的FcRn结合亲和力或血清半衰期公开(公告)号：US07361740B2
公开(公告)日：2008-04-22
申请号：US10822300
申请日：2004-04-09
CPC分类号： C07K16/249 , C07K16/00 , C07K16/082 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
摘要翻译： 本发明提供IgG类型的修饰抗体，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一个不同于 其存在于未修饰的抗体中，从而与未修饰的抗体相比改变对FcRn的结合亲和力和/或血清半衰期。
-
公开(公告)号：US07365168B2
公开(公告)日：2008-04-29
申请号：US11102621
申请日：2005-04-08
申请人： Paul Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
发明人： Paul Hinton , Naoya Tsurushita , J. Yun Tso , Maximiliano Vasquez
CPC分类号： C07K16/00 , C07K16/082 , C07K16/249 , C07K16/2809 , C07K16/2833 , C07K16/2866 , C07K2317/21 , C07K2317/52 , C07K2317/732
摘要： The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
-
公开(公告)号：US20080107595A1
公开(公告)日：2008-05-08
申请号：US11581944
申请日：2006-10-16
IPC分类号： A61K39/395 , C07K16/18 , A61K51/00 , A61P43/00 , C12N5/06
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii), two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
摘要翻译： 本发明涉及抗CCR5抗体，其包含（i）两条轻链，每条轻链包含命名为pVK：HuPRO140-VK（ATCC保藏号PTA-4097）的质粒的表达产物，和（ii）两个重的 每个重链包含命名为pVg1：HuPRO140HG2-VH（ATCC保藏号PTA-4098）的质粒或称为pVg1：HuPRO140（mutB + D + I）-VH的质粒（ATCC保藏号PTA- 4099）或其与人细胞表面上的CCR5结合的片段。
-
公开(公告)号：US07851600B2
公开(公告)日：2010-12-14
申请号：US11581944
申请日：2006-10-16
IPC分类号： C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/24 , C07K2317/76
摘要： The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO140-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVg1:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmid designated pVg1:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.
摘要翻译： 本发明涉及抗CCR5抗体，其包含（i）两条轻链，每条轻链包含命名为pVK：HuPRO140-VK（ATCC保藏号PTA-4097）的质粒的表达产物，和（ii）两条重链 每个重链包含称为pVg1：HuPRO140HG2-VH（ATCC保藏号PTA-4098）的质粒或称为pVg1：HuPRO140（mutB + D + I）-VH（ATCC保藏号PTA-4099）的质粒的表达产物 ）或其与人细胞表面上的CCR5结合的片段。
-
公开(公告)号：US08591894B2
公开(公告)日：2013-11-26
申请号：US12976282
申请日：2010-12-22
申请人： David M Holtzman , Ronald DeMattos , Kelly R. Bales , Steven M. Paul , Naoya Tsurushita , Maximiliano Vasquez
发明人： David M Holtzman , Ronald DeMattos , Kelly R. Bales , Steven M. Paul , Naoya Tsurushita , Maximiliano Vasquez
IPC分类号： A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ.
摘要翻译： 描述了以预防和治疗形成淀粉样斑块为特征的病症的治疗方法。 该方法使用人源化抗体，其从人类生物流体中螯合可溶性Aβ肽，或者优选特异性结合淀粉样蛋白β肽Abeta位置13-28中包含的表位。
-
公开(公告)号：US20110158986A1
公开(公告)日：2011-06-30
申请号：US12976282
申请日：2010-12-22
申请人： David M. Holtzman , Ronald DeMattos , Kelly R. Bales , Steven M. Paul , Naoya Tsurushita , Maximiliano Vasquez
发明人： David M. Holtzman , Ronald DeMattos , Kelly R. Bales , Steven M. Paul , Naoya Tsurushita , Maximiliano Vasquez
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ.
摘要翻译： 描述了以预防和治疗形成淀粉样斑块为特征的病症的治疗方法。 该方法采用螯合可溶性A＆Bgr的人源化抗体 来自人类生物流体的肽或其优选特异性结合淀粉样蛋白β肽A＆bgr的第13-28位含有的表位。
-
公开(公告)号：US20060039906A1
公开(公告)日：2006-02-23
申请号：US11224623
申请日：2005-09-12
申请人： David Holtzman , Ronald DeMattos , Kelly Bales , Steven Paul , Naoya Tsurushita , Maximiliano Vasquez
发明人： David Holtzman , Ronald DeMattos , Kelly Bales , Steven Paul , Naoya Tsurushita , Maximiliano Vasquez
IPC分类号： C07K16/44 , A61K39/395
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble Aβ peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide Aβ.
摘要翻译： 描述了以预防和治疗形成淀粉样斑块为特征的病症的治疗方法。 该方法使用人源化抗体，其从人类生物流体中螯合可溶性Aβ肽，或者优选特异性结合淀粉样蛋白β肽Abeta位置13-28中包含的表位。
-
公开(公告)号：US20050090648A1
公开(公告)日：2005-04-28
申请号：US10476265
申请日：2002-04-26
CPC分类号： C07K16/18 , A61K2039/505 , C07K2317/24
摘要： Humanized forms of mouse antibody 3D6 that retain the binding properties of mouse 3D6 are disclosed. Also disclosed are processes for making the humanized antibody, intermediates for making the humanized antibodies, including, nucleotide sequences, vectors, transformed host cells, and methods of using the humanized antibody to treat, prevent, alleviate, reverse, or otherwise ameliorate symptoms or pathology or both, that are associated with Down's syndrome or pre-clinical or clinical Alzheimer's disease or cerebral amyloid angiopathy.
摘要翻译： 公开了保留小鼠3D6的结合特性的小鼠抗体3D6的人源化形式。 还公开了制备人源化抗体的方法，用于制备人源化抗体的中间体，包括核苷酸序列，载体，转化的宿主细胞，以及使用人源化抗体治疗，预防，缓解，逆转或以其他方式改善症状或病理学的方法 或两者都与唐氏综合征或临床前或临床阿尔茨海默病或脑淀粉样血管病相关。
-
公开(公告)号：US20050075488A1
公开(公告)日：2005-04-07
申请号：US10484280
申请日：2002-07-18
申请人： Stuart Bright , Audrey Jia , Stuart Kuhstoss , Joseph Vincent Manetta , Naoya Tsurushita , Maximiliano Vasquez
发明人： Stuart Bright , Audrey Jia , Stuart Kuhstoss , Joseph Vincent Manetta , Naoya Tsurushita , Maximiliano Vasquez
CPC分类号： C07K16/245 , A61K2039/505 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/73 , C07K2317/76
摘要： The present invention encompasses high affinity antibodies that neutralize IL-1β activity in vivo. These antibodies can be used to treat various diseases such as rheumatoid arthritis and osteoarthritis.
摘要翻译： 本发明包括在体内中和IL-1β活性的高亲和力抗体。 这些抗体可用于治疗各种疾病，例如类风湿性关节炎和骨关节炎。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.031 秒)
